エピソード

  • S2 Ep5 | Lynn Durham, President & CEO, Georgia Core, A Neutral Party In Cancer Care: Collaboration, Clinical Trials, and Quality of Life

    S2 Ep5 | Lynn Durham, President & CEO, Georgia Core, A Neutral Party In Cancer Care: Collaboration, Clinical Trials, and Quality of Life
    2026/01/13
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESIn this incredible, timely, and informative episode of VITALS, Maria Thacker, the CEO of Georgia Life Sciences, interviews Lynn Durham, President and CEO of Georgia Core, who discusses her journey from government and politics to leading a nonprofit focused on cancer care. Georgia Core, founded in 2003, aims to improve cancer care through research, education, and advocacy. The organization collaborates with healthcare systems across Georgia, emphasizing patient-centered care and clinical trials. Durham highlighted the importance of diversifying funding sources, including federal grants and industry partnerships. She also mentioned the Georgia Cancer Trial Finders program and a statewide colorectal cancer awareness campaign. Durham's personal experiences with cancer and her commitment to improving cancer care drive her work.Lynn Durham's Journey and Role at Georgia CoreMaria introduces Lynn Durham, President and CEO of Georgia Core, and highlights the importance of her work in the oncology space.Lynn shares her career journey, starting with her work at Georgia Tech in government and politics, and her transition to becoming the president's chief of staff.Lynn discusses her personal connection to cancer, having survived thyroid, breast, and chronic myeloid leukemia, and her involvement with Georgia Core's survivorship advisory board.Lynn explains how she was asked to lead Georgia Core after the previous president retired, despite her initial plans to pursue higher education.Georgia Core's Mission and StructureMaria asks about the meaning of "core," which stands for the Center for Oncology Research and Education.Lynn explains that Georgia Core was founded in 2003 by Governor Roy Barnes to ensure Georgians had access to cancer care without leaving the state.Georgia Core works with doctors, hospitals, and healthcare systems to improve cancer care through research, education, and advocacy.The organization is not patient-facing but focuses on connecting researchers, providers, and patients to improve cancer care outcomes.Collaboration and Advocacy EffortsLynn emphasizes the importance of collaboration among physicians, administrators, and researchers to improve cancer care in Georgia.Georgia Core has a strong board of 20 members, mostly oncologists, who work together to benefit Georgians.The organization works with various healthcare systems across the state, including Northside, Emory, and Valdosta, to address different cancer care needs in different regions.Lynn highlights the role of advisory boards and regional cancer coalitions in ensuring patient voices are integrated into research and care delivery.Funding and DiversificationLynn discusses the funding sources for Georgia Core, including state funds, federal grants, and industry partnerships.The organization has diversified its funding sources to include federal grants and industry sponsorships, reducing dependence on state funds.Georgia Core also generates funds through license plates and a state income tax line for cancer research.The organization funds seed grants for university researchers and supports nonprofits to provide cancer screenings and other services.Policy and Advocacy ChallengesLynn addresses the challenges posed by uncertain federal and state policies on healthcare access, research funding, and drug pricing.The uncertainty has impacted Georgia Core's ability to plan and secure funding for long-term projects.The organization has had to adapt to changes in funding availability, including the need to hire clinical research nurses and navigators.Lynn emphasizes the importance of advocacy and working with legislators to ensure continued support for cancer care initiatives.Workforce Development and Oncology TalentLynn discusses the challenges of workforce development in the oncology field, including recruitment and retention in rural areas.Georgia Core has established a Cancer Care Access Committee to address workforce issues, including oncology nurses, PAs, and navigators.The organization is working with the Technical College System of Georgia and AHEC to introduce students to oncology careers and develop apprenticeship programs.Lynn highlights the need for legislative support to provide loan forgiveness for healthcare professionals working in rural areas.Innovative Programs and InitiativesLynn introduces the Georgia Cancer Trial Finders program, which helps patients and caregivers find clinical trials for various cancer types.The program has received over 90 referrals and is proving to be a valuable resource for patients and researchers.Georgia Core has launched a statewide colorectal cancer awareness campaign targeting people aged 25 to 54, aiming to increase awareness and early detection.The campaign includes creative elements like "weird looking stools" in bars and coffee shops to raise awareness about colorectal cancer symptoms.Personal Motivation and Future OutlookLynn shares her ...
    続きを読む 一部表示
    34 分
  • S2 Ep4 | Samir Patel, CEO, Moonlight Therapeutics, Homegrown Innovation: Microneedle Stamps for the Food Allergy Epidemic

    S2 Ep4 | Samir Patel, CEO, Moonlight Therapeutics, Homegrown Innovation: Microneedle Stamps for the Food Allergy Epidemic
    2025/12/16
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESIn this incredible, timely, and informative episode of VITALS, Maria Thacker, the CEO of Georgia Life Sciences, interviews Dr. Samir Patel, President and CEO of Moonlight Therapeutics, who discusses the company's development of a micro-needle stamp for food allergy treatment. The technology, which aims to reduce side effects and improve patient adherence, is currently undergoing clinical trials. Moonlight has raised $9 million in SBIR funds and secured additional support from the NIH and the DoD. Patel emphasized the importance of simplifying product design and understanding regulatory requirements. He also highlighted the need for better ecosystem support in Georgia, advocating for more active networking and marketing of local innovations.Introduction and Background of Dr. Samir PatelMaria Thacker introduces the podcast and welcomes Dr. Samir Patel, President and CEO of Moonlight Therapeutics.Dr. Patel shares his background as an engineer turned entrepreneur, co-founding ClearSide Biomedical.He discusses his educational background, including his PhD from Georgia Tech and dual Bachelor's degrees from UC Berkeley.Dr. Patel explains his initial interest in the tech world and his pivot to the life sciences after a co-op at a J&J company.Moonlight Therapeutics and Food Allergy FocusDr. Patel talks about his move to Georgia and his interest in food allergies, which led him to start Moonlight Therapeutics.He describes the initial challenges and the unmet need in the food allergy space.Dr. Patel shares how he connected with a Georgia Tech professor to start researching food allergies.The company officially formed in 2019, focusing on a micro-needle stamp approach to food allergy care.Technology and Clinical TrialsDr. Patel explains the microneedle stamp technology and its benefits over existing food allergy treatments.He discusses the current approved therapy for food allergies and its limitations.The microneedle stamp aims to deliver allergens through the skin, avoiding GI side effects and making the treatment more convenient.Dr. Patel highlights the importance of user experience and simplicity in product design.Regulatory Challenges and Investor LandscapeDr. Patel shares insights on the regulatory process and the importance of understanding FDA requirements.He discusses the challenges of being a combination product and the impact on investor interest.Dr. Patel explains how the regulatory landscape has influenced his approach to product development.He emphasizes the need for efficient use of capital and resources in the regulatory process.Clinical Trial and Future PlansDr. Patel talks about the upcoming clinical trial for Moonlight Therapeutics, focusing on safety and efficacy.He explains the importance of finding a safe dose and monitoring immune markers in patients.The trial will be conducted in Georgia, with sites in South Carolina and other Southeastern states.Dr. Patel shares the company's long-term goals, including expanding the treatment to other allergens and developing combination therapies.Advice for First-Time FoundersDr. Patel provides advice for first-time founders, emphasizing the importance of intellectual property and market understanding.He discusses the need for a clear regulatory pathway and the role of non-dilutive funding in early-stage development.Dr. Patel highlights the importance of networking and advocating for the company within the ecosystem.He shares his experience with government grants and the value of leveraging multiple funding sources.Impact of Non-Dilutive FundingDr. Patel explains how non-dilutive funding, such as SBIR grants, can support early-stage companies.He discusses the challenges of balancing research and product development to attract investors.Dr. Patel emphasizes the importance of using government grants to move the product through the development process.He shares his experience with the DoD grant and the need for creative funding strategies.Georgia Ecosystem and Future GoalsDr. Patel discusses the strengths and gaps in the Georgia life sciences ecosystem.He emphasizes the need for better marketing and advocacy for Georgia's research and innovation.Dr. Patel highlights the importance of networking and engaging with larger ecosystems to attract investment and support.He shares his vision for the future of Moonlight Therapeutics and the broader impact on food allergy treatment.Personal Insights and Final ThoughtsDr. Patel shares a personal anecdote about gardening and its connection to starting companies.He explains the parallels between growing plants and developing successful products.Dr. Patel expresses his gratitude for the support and opportunities in Georgia.Maria Thacker concludes the podcast, thanking Dr. Patel and the listeners, and highlighting the importance of community engagement and advocacy.About Georgia Life SciencesAs the leading advocate for the state’s dynamic and diverse life sciences ...
    続きを読む 一部表示
    32 分
  • S2 Ep3 | Mike Walker, Exec Director, Microsoft, Augmenting and Accelerating Life Sciences Innovation With AI

    S2 Ep3 | Mike Walker, Exec Director, Microsoft, Augmenting and Accelerating Life Sciences Innovation With AI
    2025/12/02
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESIn this incredible, timely, and informative episode of VITALS, Maria Thacker, the CEO of Georgia Life Sciences, interviews Mike Walker, Vice President of Health and Life Sciences at Microsoft, for a rubust discussion on the integration of AI in the life sciences industry. He emphasized the importance of focusing on non-sexy use cases like SOPs and document generation to enhance productivity and compliance. Walker highlighted the need for trustworthy data, governance, and a zero-trust architecture to ensure regulatory compliance. He also stressed the importance of AI in talent retention and acquisition, particularly in small and mid-size biotech companies. Looking ahead, he predicted significant advancements in biohacking and quantum computing, and advocated for a proactive approach in building the "factory of the future."IntroductionMaria Thacker introduces the podcast and welcomes Mike Walker, Vice President of Health and Life Science at Microsoft.Mike Walker shares his background in corporate strategy, innovation management, and his time at Gartner as VP of Technology Innovation and CTO Strategy.Mike discusses his role at Microsoft, emphasizing his work as a strategic advisor, a bridge between Microsoft and partners, and his experience in writing books and speaking at events.Maria highlights the importance of AI in the life sciences industry and the growing manufacturing capacity in Georgia, mentioning companies like Takeda, Burning Rock, and J&J.AI in Life Sciences: Use Cases and Non-Sexy ApplicationsMaria asks Mike about the role of AI in the life sciences industry, specifically in pharma and biotech.Mike advises focusing on non-sexy use cases like SOPs (Standard Operating Procedures) and document generation for regulatory submissions.He emphasizes the importance of data trustworthiness and the need to upskill talent within organizations to adopt AI.Mike suggests avoiding advanced autonomous agents unless the organization is a leading innovator in AI.Generational Divide and AI IntegrationMaria clarifies that Mike is referring to AI tools and not human agents when discussing the generational divide.Mike explains the integration of AI tools like Copilot in Microsoft 365 and the importance of creating a platform of intelligence within organizations.Maria shares a TikTok example of a woman discovering AI tools in her new company and the potential for AI to create efficiencies and save costs.Mike discusses the architectural approach of creating a platform of intelligence and the importance of having AI capabilities accessible like an app store.Regulatory and Geopolitical Forces Driving AI AdoptionMaria asks why life sciences companies should care about AI, especially in a regulated industry.Mike explains the amplification of workforce productivity through AI and the importance of AI in regulatory compliance and geopolitical aspects.He discusses the impact of regulatory changes, tariffs, and high-risk jurisdictions on supply chain networks and the role of AI in optimizing operations.Mike highlights the aging population and the need for AI to supplement workforce efforts and create a framework for talent retention and acquisition.AI in New Product Introduction and Tech TransferMaria and Mike discuss the importance of AI in new product introduction (NPI) and tech transfer.Mike explains the challenges of hitting a patent cliff and the need for AI to maximize patent life cycles and improve NPI processes.He emphasizes the role of AI in creating repeatability and reducing the time to onboard new drugs.Maria and Mike agree on the importance of AI in small and mid-size biotech companies to stay competitive and agile.Credibility and Governance of AI in Life SciencesMaria asks about the credibility of AI and the need for guardrails and fallback systems.Mike emphasizes the importance of trustworthy data, governance, and zero-trust architecture to ensure regulatory compliance.He discusses the need for AI systems to be evergreen and agile in adapting to new regulatory requirements.Maria and Mike agree on the importance of having SOPs in place to track data and ensure compliance.Practical Steps for Small Companies to Integrate AIMaria asks about practical steps for small companies to integrate AI.Mike suggests starting small, using AI to help with upskilling and adopting AI tools like Copilot.He recommends hiring AI digital natives to shadow existing employees and share best practices.Mike emphasizes the importance of investing in talent and upskilling the existing workforce to leverage institutional knowledge.Future of AI in Life Sciences: Short-Term and Long-Term ImpactMaria asks about the future of AI in life sciences and its impact on patients and the industry.Mike predicts that biohacking and quantum computing will have significant impacts in the next 5-10 years.He discusses the potential of biohacking to create meaningful data and human augmentation.Mike ...
    続きを読む 一部表示
    46 分
  • S2 Ep2 | David Crean, General Partner, 1004 Ventures, Discusses The Knowledge Needed To Optimize The Capital Stack and Valuation

    S2 Ep2 | David Crean, General Partner, 1004 Ventures, Discusses The Knowledge Needed To Optimize The Capital Stack and Valuation
    2025/11/13
    WELCOME TO VITALS, THE PULSE OF GEORGIA LIFE SCIENCESIn this episode of Vitals, Maria Thacker, the CEO of Georgia Life Sciences, interviews David Crane, a venture partner at 1004 Venture Partners, about the biotech industry in Georgia as well as on a national level. David, with a PhD in physics and an MBA, discusses the importance of a diverse funding stack, including NIH, VCs, family offices, and strategic partnerships. He emphasizes the need for founders to understand investor preferences and the importance of risk mitigation. David highlights the current economic challenges affecting investment strategies and the necessity for founders to think like investors. He also touches on the potential of family offices and the importance of business acumen beyond scientific expertise.David Crane's Background and Role in Venture CapitalMaria Thacker introduces David Crane, highlighting his role at 1004 Venture Partners and his expertise from the West Coast.David Crane shares his background, including a PhD in physics and an MBA, and his experience in biopharma, private equity, VC, and investment banking.David discusses his move from Buffalo, New York, to California and his current time split between the Bay Area and San Diego.Maria and David discuss their experiences at various biotech conferences, including the BIO Convention and the JP Morgan Healthcare Conference.Capital and Risk in BiotechMaria asks David about the recipe for a resilient funding stack for early-stage R&D in biotech, mentioning various funding sources like NIH, VCs, family offices, and strategic partnerships.David emphasizes the importance of pursuing multiple funding avenues and understanding the investor's needs and preferences.Maria shares feedback from an investor conference in the Southeast, noting the region's potential but lack of sophistication in investor relations.David advises founders to understand their investors' investment theses, fund sizes, and portfolio companies to customize their pitches and increase their chances of success.Mitigating Risk and Building TeamsDavid discusses the inherent risk in the biotech industry and the importance of risk mitigation through key experiments and milestones.He emphasizes the need for founders to focus on proof of concept, reimbursement, and strategic partnerships to improve their odds of success.Maria and David discuss the challenges of building teams in emerging markets and the role of mentors and networks in supporting founders.David highlights the importance of understanding the investor's perspective and the need for founders to think like investors when building their business cases.Impact of Economic Factors on Investment StrategiesDavid addresses the current challenging investment environment, including liquidity crises, macroeconomic challenges, and cautious investor behavior.He advises founders to have a capital stack mentality and explore multiple funding sources, including NIH, BARDA, and family offices.David notes that larger funds are increasingly looking at earlier-stage investments and the importance of transformative technologies in today's market.Maria and David discuss the potential for family offices to invest in life sciences and the need for education and domain expertise in this space.Founder-Investor Fit and Business AcumenDavid emphasizes the importance of founders thinking like investors and understanding the strategic value of their VCs beyond valuation.He advises founders to look at the VC's network, diligence, experience, and ability to provide mentorship and support.Maria and David discuss the challenges of scientific founders transitioning to CEO roles and the need for business acumen and team-building.David highlights the importance of having a viable business model and articulating a clear pathway to success for investors.Focus Areas in Healthy Aging and LongevityDavid shares his focus on cardiometabolic diseases, neurodegeneration, and oncology as key areas in healthy aging and longevity.He discusses the potential of integrating AI in neurodegenerative research and the progress being made in oncology.David emphasizes the importance of improving quality of life rather than just extending lifespan.Maria and David discuss the role of associations like Georgia Life Sciences in supporting entrepreneurs and the importance of policy advocacy.Role of Associations in Supporting Emerging HubsDavid praises the role of associations like Georgia Life Sciences in convening industry events, advocating for policy, and supporting innovation.He highlights the importance of building relationships with academic institutions and human capital in emerging hubs.Maria and David discuss the challenges of engaging small companies in policy matters and the increasing importance of policy in the biotech industry.David emphasizes the need for organizations to help entrepreneurs navigate the complexities of innovation and policy.Final Thoughts and Personal InsightsDavid shares a ...
    続きを読む 一部表示
    35 分
  • S2 Ep1 | John Crowley, CEO, BIO, Discusses The Biology Century and The Convergence of Public Health, Economic Growth, and National Security

    S2 Ep1 | John Crowley, CEO, BIO, Discusses The Biology Century and The Convergence of Public Health, Economic Growth, and National Security
    2025/09/30
    Welcome to VITALS Season 2!To kick off the new season, the CEO of Georgia Life Sciences, Maria Thacker-Goethe, is joined in studio by the President and CEO of BIO, John Crowley, who shared his journey from business to biotech after his daughter Megan was diagnosed with Pompe Disease. He emphasized the importance of time in biotech, highlighting the transformation of cystic fibrosis treatment from a death sentence to a normal life expectancy. Crowley discussed the role of AI and machine learning in accelerating drug development, the need for a modernized FDA, and the importance of access to medicines. He advocated for a 21st Century Access Act to address barriers to medication. Crowley also mentioned his military service and his role in advocating for biotechnology to enhance public health, economic growth, and national security.John Crowley's Introduction and Personal BackgroundMaria Thacker Gothe introduces John Crowley, President and CEO of BIO, the Biotechnology Innovation Organization.John Crowley shares his background, including his early career in business and his transition into the world of science and medicine.John recounts the diagnosis of his daughter Megan with Pompe Disease, a rare form of muscular dystrophy, and the emotional journey that followed.He describes the initial shock and subsequent determination to learn about the disease and find a treatment.The Journey to Develop a Treatment for Pompe DiseaseJohn explains the process of learning about Pompe Disease, including the genetic aspects and the buildup of glycogen in Megan's muscles.He details the early research efforts and the realization that time was crucial in developing a treatment.John highlights the importance of collaboration with researchers and the development of a medicine that saved Megan and her brother Patrick's lives.He shares the progress his children have made, including Megan's education and career in social work and Patrick's work in a flower shop.John Crowley's Role at BIO and Advocacy for BiotechnologyMaria Thacker Gothe asks John about his priorities at BIO and how he sees biotechnology unleashing its potential.John emphasizes the importance of science policy, the need for more capital, and a business mindset in advancing biotechnology.He discusses the success stories in biotechnology, such as the transformation of cystic fibrosis treatment, and the need for more breakthroughs.John outlines the three main reasons for supporting biotechnology: public health, economic growth, and national security.The Role of AI and Machine Learning in BiotechnologyMaria and John discuss the potential of AI and machine learning in compressing the development pipeline in biotechnology.John shares examples of AI's current and future impact on medicine, including improving physician efficiency, aiding in diagnosis, and enhancing drug development.He highlights the potential of AI in understanding complex biological systems and improving clinical trial efficiency.John emphasizes the need for ethical principles and guardrails to ensure AI's responsible use in biotechnology.Challenges and Opportunities in BiotechnologyMaria and John discuss the challenges of accessing capital and the importance of reducing the time and cost of developing new medicines.John mentions the role of family offices, sovereign wealth funds, and new pools of capital in supporting biotechnology.He emphasizes the need for a modernized FDA and a more efficient clinical trial paradigm to speed up innovation.John highlights the importance of storytelling and advocacy in building support for biotechnology and ensuring access to life-saving medicines.Building a Successful Biotech Ecosystem in GeorgiaMaria asks John for advice on building a successful biotech ecosystem in Georgia.John emphasizes the importance of purposeful investment in workforce development, from high school STEM programs to vocational training and university education.He highlights the need for a pro-business environment and entrepreneurship culture to attract and retain biotech companies.John suggests looking at best practices from other successful biotech hubs and customizing them to Georgia's needs.The Importance of Access to MedicinesJohn discusses the moral obligation to ensure access to life-saving medicines and the role of the social contract between patients, insurers, and pharmaceutical companies.He criticizes the current system of step edits and prior authorizations, which can delay patient access to necessary treatments.John calls for a 21st Century Access Act to address barriers to access and ensure that all patients can receive the medicines they need.He emphasizes the need for transparency and reform in the pharmacy benefit manager (PBM) system to reduce costs and improve patient access.Personal Reflections and Future GoalsMaria asks John to share something most people don't know about him.John reveals that he is a grandfather to two beautiful grandchildren and has served in the United ...
    続きを読む 一部表示
    40 分
  • From Georgia Tech to Global Impact: Porex's Journey in Life Sciences with Avi Robbins

    From Georgia Tech to Global Impact: Porex's Journey in Life Sciences with Avi Robbins
    2025/04/11
    In this episode of the Georgia Life Sciences Podcast, host Maria Thacker Goethe sits down with Avi Robbins, President of the Porex Life Sciences Institute, to discuss how Porex has evolved from a Georgia Tech-founded startup into a global leader in life sciences. Avi shares insights on public-private partnerships, the role of research collaborations, and how Porex is driving innovation in medical devices and diagnostic testing. Learn more about Porex and its impact on Georgia’s life sciences ecosystem in this insightful conversation! RESOURCES RELATED TO THIS EPISODE
    • Visit https://www.porexlifesciences.com/
    • Follow Avi Robbins on LinkedIn at https://www.linkedin.com/in/avirobbins/
    • And visit https://www.galifesciences.org/ to learn more about Georgia Life Sciences
    CREDITS
    • Theme Music🎵AG_Music from Pond5
    • Produced by ChatWithLeadersMedia.com
    See omnystudio.com/listener for privacy information.
    続きを読む 一部表示
    13 分
  • Regulatory Science in Georgia: UGA’s Role in Preparing our Future Workforce with Johnna Hodges

    Regulatory Science in Georgia: UGA’s Role in Preparing our Future Workforce with Johnna Hodges
    2025/03/28
    In this episode of the Georgia Life Sciences Podcast, host Maria Thacker-Goethe speaks with Johnna Hodges, Assistant Director of UGA’s Biomedical and International Biomedical Regulatory Sciences Program. They explore the growing need for regulatory professionals in the life sciences sector, how UGA’s program is preparing students for careers in regulatory affairs, clinical trials, and drug safety, and the evolving landscape of medtech education. Whether you're a student, an industry professional, or simply curious about the regulatory side of biotech, this episode offers key insights into an exciting and expanding field. Tune in now! RESOURCES RELATED TO THIS EPISODE
    • Learn more about UGA's College of Pharmacy Department of International Biomedical Regulatory Sciences (IBRS) at https://rx.uga.edu/departments/academic/ibrs/
    • Follow Johnna Hodges on LinkedIn at https://www.linkedin.com/in/johnna-hodges/
    • And visit https://www.galifesciences.org/ to learn more about Georgia Life Sciences
    CREDITS
    • Theme Music🎵AG_Music from Pond5
    • Produced by ChatWithLeadersMedia.com
    See omnystudio.com/listener for privacy information.
    続きを読む 一部表示
    9 分
  • VITALS S1 Trailer | The Season Ahead With Maria Thacker-Goethe, CEO, Georgia Life Sciences

    VITALS S1 Trailer | The Season Ahead With Maria Thacker-Goethe, CEO, Georgia Life Sciences
    2025/03/12
    Welcome to VITALS, The Georgia Life Sciences Podcast—your source for the latest insights, innovations, and industry developments in Georgia’s thriving life sciences ecosystem. This podcast highlights how Georgia Life Sciences is driving industry growth, advancing policies, and fostering strategic partnerships that support biotech professionals and companies. Each episode features conversations with industry leaders, policymakers, and innovators who are shaping the future of biotech and medtech in Georgia and beyond. Whether you're a decision-maker, entrepreneur, or passionate about life sciences, this series offers actionable insights, inspiring success stories, and key trends that impact businesses and careers in the sector. Subscribe to the Georgia Life Sciences Podcast on your favorite platform and follow us on social media for updates on new episodes.

    About Georgia Life Sciences

    As the leading advocate for the state’s dynamic and diverse life sciences sector, Georgia Life Sciences’ mission is to advance the growth of Georgia’s life sciences industry through partnerships and initiatives that accelerate innovation, investment, and job creation. To accomplish this mission, Georgia Life Sciences conducts economic development activities; advocates on behalf its members on public policy matters; educates the public about the benefits of life sciences research and product development; and provides a network for idea exchange and cooperation.

    For more information on the impactful work, to join as a member, or provide support to the mission, please visit Georgia Life Sciences at https://www.galifesciences.org/
    続きを読む 一部表示
    2 分